共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
本文应用抗-HGV酶联免疫法(EIA)和逆转录套式聚合酶链反应法(RT-PCR)检测150份乙型、120份丙型、15份戊型和49份非甲-戊型肝炎患者血清。结果显示:乙肝、丙肝、戊肝和非甲-戊型肝炎患者中抗-HGV抗体的阳性率分别为22.0%(33/150)、25.0%(30/120)、33.3%(5/15)和40.1%(20/49)。其中乙型、丙型、戊型和非甲-戊型肝炎的抗-HGV抗体阳性者中,HGV RNA的阳性率分别为58.3%(7/12)、60.0%(6/10)、40.0%(2/5)和45.5%(9/12)。说明GBV-C/HGV可与HBV、HCV或HEV合并感染,该病毒可能引起临床型肝炎。 相似文献
3.
妊娠期暴发型肝功能衰竭的研究 总被引:14,自引:0,他引:14
目的探讨妊娠期暴发型肝功能衰竭(FHFP)的临床,生化,病原学特点。方法观察21例FHFP临床表现,并分析实验室资料,13例作肝组织学检查。结果乙型肝炎病毒感染7例,乙型肝炎病毒、戊型肝炎病毒重叠感染2例。FHFP血清白蛋白极显著低于妊娠期急性肝炎和慢性肝炎,分别为(25.19±6.95)、(33.17±3.44)及(33.80±3.78)g/L(均P<0.01)。肝组织学诊断为,存活的6例中,急性肝炎1例,慢性肝炎4例,瘀胆型肝炎1例。死亡7例中,慢性肝炎4例,瘀胆型肝炎2例,产前子痫肝损害1例。结论肝炎病毒是FHFP的病因之一。低蛋白血症在FHFP发病中起着重要作用;FHFP可能是一种独特的综合征。 相似文献
4.
目的 了解静脉毒瘾者乙型肝炎病毒(HBV),丙型肝炎病毒(HCV)及庚型肝炎病毒的感染状况。方法 对广东省江门市120例静脉毒瘾者血浆的HBV、HCV和HGV的标记物进行了检测,采用ELISA法检测HBsAg,HBeAg,抗-HBc,抗-HBe,抗-HBs,抗-HCV;逆转录聚合酶链反应(RT-PCR)检测HGV RNA。结果 120例静脉毒瘾者中HBsAg阳性有13例(10.83%),抗-HBs阳性41例(34.71%),单项抗-HBc阳性7例(5.83%),抗-HCV阳性89例(74.17%),HGV RNA阳性28例(23.33%)。13例HBsAg阳性中9例抗-HCV阳性,3例HGV RNA阳性;7例单项抗-HBc阳性中5例抗-HCV阳性,2例HGV RNA阳性;28例HGV RNA阳性中20例抗-HCV阳性;2例HBsAg、抗-HCV、HGV RNA同时阳性。结论 静脉毒瘾者是HCV和HGV的高危感染人群;HBV,HCV和HGV三种病毒的感染之间在静脉毒瘾者中无相关性。 相似文献
5.
6.
Rebeca Sanabria Mateos Niamh M Hogan Dimitri Dorcaratto Helen Heneghan Venkatesh Udupa Donal Maguire Justin Geoghegan Emir Hoti 《World journal of hepatology》2016,8(4):226-230
AIM: To evaluate the outcomes of two-stage liver transplant at a single institution, between 1993 and March 2015.METHODS: We reviewed our institutional experience with emergency hepatectomy followed by transplantation for fulminant liver failure over a twenty-year period. A retrospective review of a prospectively maintained liver transplant database was undertaken at a national liver transplant centre. Demographic data, clinical presentation, preoperative investigations, cardiocirculatory parameters, operative and postoperative data were recorded.RESULTS: In the study period, six two-stage liver transplants were undertaken. Indications for transplantation included acute paracetamol poisoning(n = 3), fulminant hepatitis A(n = 1), trauma(n = 1) and exertional heat stroke(n = 1). Anhepatic time ranged from 330 to 2640 min. All patients demonstrated systemic inflammatory response syndrome in the first post-operative week and the incidence of sepsis was high at 50%. There was one mortality, secondary to cardiac arrest 12 h following re-perfusion. Two patients required re-transplantation secondary to arterial thrombosis. At a median follow-up of 112 mo, 5 of 6 patients are alive and without evidence of graft dysfunciton.CONCLUSION: Two-stage liver transplantation represents a safe and potentially life-saving treatment for carefully selected exceptional cases of fulminant hepatic failure. 相似文献
7.
Fernando Mendes Paschoal Jr Ricardo Carvalho Nogueira Karla De Almeida Lins Ronconi Marcelo de Lima Oliveira Manoel Jacobsen Teixeira Edson Bor-Seng-Shu 《World journal of hepatology》2016,8(22):915-923
Acute liver failure, also known as fulminant hepatic failure(FHF), embraces a spectrum of clinical entities characterized by acute liver injury, severe hepatocellular dysfunction, and hepatic encephalopathy. Cerebral edema and intracranial hypertension are common causes of mortality in patients with FHF. The management of patients who present acute liver failure starts with determining the cause and an initial evaluation of prognosis. Regardless of whether or not patients are listed for liver transplantation, they should still be monitored for recovery, death, or transplantation. In the past, neuromonitoring was restricted to serial clinical neurologic examination and, in some cases, intracranial pressure monitoring. Over the years, this monitoring has proven insufficient, as brain abnormalities were detected at late and irreversible stages. The need for real-time monitoring of brain functions to favor prompt treatment and avert irreversible brain injuries led to the concepts of multimodal monitoring and neurophysiological decision support. New monitoring techniques, such as brain tissue oxygen tension, continuous electroencephalogram, transcranial Doppler, and cerebral microdialysis, have been developed. These techniques enable early diagnosis of brain hemodynamic, electrical, and biochemical changes, allow brain anatomical and physiological monitoring-guided therapy, and have improved patient survival rates. The purpose of this review is to discuss the multimodality methods available for monitoring patients with FHF in the neurocritical care setting. 相似文献
8.
Darin S Krygier Urs P Steinbrecher Martin Petric Siegfried R Erb Stephen W Chung Charles H Scudamore Andrzej K Buczkowski Eric M Yoshida 《World journal of gastroenterology : WJG》2009,15(32):4067-4069
Parvovirus B19 induced acute hepatitis and hepatic failure have been previously reported, mainly in children. Very few cases of parvovirus induced hepatic failure have been reported in adults and fewer still have required liver transplantation. We report the case of a 55-year-old immunocompetent woman who developed fulminant hepatic failure after acute infection with Parvovirus B19 who subsequently underwent orthotopic liver transplantation. This is believed to be the first reported case in the literature in which an adult patient with fulminant hepatic failure associated with acute parvovirus B19 infection and without hematologic abnormalities has been identified prior to undergoing liver transplantation. This case suggests that Parvovirus B19 induced liver disease can affect adults, can occur in the absence of hematologic abnormalities and can be severe enough to require liver transplantation. 相似文献
9.
10.
Castaldo ET Chari RS 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2006,8(1):29-34
There are numerous causes of acute hepatic failure (AHF). Cerebral edema, coagulopathy, renal failure, metabolic disturbances and infection are the main clinical sequelae. Patients with AHF should be stabilized when first encountered and transferred to the nearest liver transplant center, as AHF progresses quickly and is often fatal. There are few adequate medical interventions and care of patients with AHF is supportive until spontaneous recovery ensues. If recovery does not appear to occur, most causes of AHF are well accepted indications for liver transplantation. 相似文献
11.
Animal models of fulminant hepatic failure 总被引:16,自引:0,他引:16
John Terblanche ChM FCS FRCS FRCPS FACS Rosemary Hickman ChM MD 《Digestive diseases and sciences》1991,36(6):770-774
The six requirements for a satisfactory animal model of fulminant hepatic failure are reversibility, reproducibility, death from liver failure, a therapeutic window, a large animal model, and minimal hazard to personnel. Different models may be required to evaluate the various types of liver failure seen in man. The available models include surgical anhepatic and devascularization procedures, as well as hepatotoxic drug administration using agents such as carbon tetrachloride, acetaminophen, or galactosamine. Currently combined surgical and drug models appear to provide the best model but the search for the ideal models continues.Presented at the Proceedings of the International Meeting on Normal and Neoplastic Growth in Hepatology, Bari, Italy, June 1989. 相似文献
12.
目的研究组织蛋白酶B在暴发性肝衰竭小鼠肝组织中的表达。方法雄性昆明种小鼠腹腔同时注射脂多糖和D-氨基半乳糖,动态观察给药后2、4、6、8 h肝脏病理改变;以TUNEL法检测肝细胞凋亡;应用免疫组化和RT-PCR检测肝组织中组织蛋白酶B的表达。结果肝组织病理:给药后4 h出现凋亡细胞,6 h大量肝细胞凋亡,8 h以肝细胞坏死为主;TUNEL:给药后凋亡指数逐渐升高,6 h达到高峰,8 h有所降低;免疫组化:组织蛋白酶B表达2 h无明显变化(P〉0.05),4 h逐渐增加,8 h达到高峰(P〈0.05);RT-PCR:2 h组织蛋白酶B mRNA的表达量无明显变化(P〉0.05),4 h表达略有升高,6 h表达最高,8 h表达有所降低(P〈0.05)。结论组织蛋白酶B在小鼠暴发性肝衰竭肝组织中表达明显增加,提示其可能通过促进肝细胞的凋亡而参与了暴发性肝衰竭的发病。 相似文献
13.
Detry O De Roover A Coimbra C Delwaide J Hans MF Delbouille MH Monard J Joris J Damas P Belaïche J Meurisse M Honoré P 《World journal of gastroenterology : WJG》2007,13(9):1427-1430
AIM: To investigate the long-term results of liver transplantation (LT) for non-acetaminophen fulminant hepatic failure (FHF). METHODS: Over a 20-year period, 29 FHF patients underwent cadaveric whole LT. Most frequent causes of FHF were hepatitis B virus and drug-related (not acetaminophen) liver failure. All surviving patients were regularly controlled at the out-patient clinic and none was lost to follow-up. Mean follow-up was 101 mo. RESULTS: One month, one-, five- and ten-year patient survival was 79%, 72%, 68% and 68%, respectively. One month, one-, five- and ten-year graft survival was 69%, 65%, 51% and 38%, respectively. Six patients needed early (< 2 mo) retransplantation, four for primary non-function, one for early acute refractory rejection because of ABO blood group incompatibility, and one for a malignant tumor found in the donor. Two patients with hepatitis B FHF developed cerebral lesions peri-transplantion: One developed irreversible and extensive brain damage leading to death, and one suffered from deep deficits leading to continuous medical care in a specialized institution. CONCLUSION: Long-term outcome of patients transplanted for non-acetaminophen FHF may be excellent. As the quality of life of these patients is also particularly good, LT for FHF is clearly justified, despite lower graft survival compared with LT for other liver diseases. 相似文献
14.
Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure 总被引:1,自引:0,他引:1
Yang BS Ma YJ Wang Y Chen LY Bi MR Yan BZ Bai L Zhou H Wang FX 《World journal of gastroenterology : WJG》2007,13(3):462-466
AIM: To investigate the protective effect of stronger neo-minophafen C (SNMC) on fulminant hepatic failure (FHF) and its underlying mechanism.
METHODS: A mouse model of FHF was established by intraperitoneal injection of galactosamine (D-Gal N) and lipopolysaccharide (LPS). The survival rate, liver function, inflammatory factor and liver pathological change were obtained with and without SNMC treatment. Hepatoo/te survival was estimated by observing the stained mitochondria structure with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate fluorescence nick end labeling (TUNEL) method and antibodies against cytochrome C (Cyt-C) and caspase-3.
RESULTS: The levels of plasma tumor necrosis factor alpha (TNF-α), nitric oxide (NO), ET-1, interleukin-6 (IL-6), and the degree of hepatic tissue injury were decreased in the SNMC-treated groups compared with those in the model group (P 〈 0.01). However, there were no differences after different dosages administered at different time points. There was a significant difference in survival rates between the SNMC-treated groups and the model group (P 〈 0.01). The apoptosis index was 32.3% at 6 h after a low dose of SNMC, which was considerably decreased from 32.3% ± 4.7% vs 5% ± 2.83% (P 〈 0.05) to 5% on d 7. The expression of Cyt-C and caspase-3 decreased with the prolongation of therapeutic time. Typical hepatocyte apoptosis was obviously ameliorated under electron microscope with the prolongation of therapeutic time. CONCLUSION: SNMC can effectively protect liver against FHF induced by LPS/D-Gal N. SNMC can prevent hepatocyte apoptosis by inhibiting inflammatory reaction and stabilizing mitochondria membrane to suppress the release of Cyt-C and sequent activation of caspase-3. 相似文献
METHODS: A mouse model of FHF was established by intraperitoneal injection of galactosamine (D-Gal N) and lipopolysaccharide (LPS). The survival rate, liver function, inflammatory factor and liver pathological change were obtained with and without SNMC treatment. Hepatoo/te survival was estimated by observing the stained mitochondria structure with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate fluorescence nick end labeling (TUNEL) method and antibodies against cytochrome C (Cyt-C) and caspase-3.
RESULTS: The levels of plasma tumor necrosis factor alpha (TNF-α), nitric oxide (NO), ET-1, interleukin-6 (IL-6), and the degree of hepatic tissue injury were decreased in the SNMC-treated groups compared with those in the model group (P 〈 0.01). However, there were no differences after different dosages administered at different time points. There was a significant difference in survival rates between the SNMC-treated groups and the model group (P 〈 0.01). The apoptosis index was 32.3% at 6 h after a low dose of SNMC, which was considerably decreased from 32.3% ± 4.7% vs 5% ± 2.83% (P 〈 0.05) to 5% on d 7. The expression of Cyt-C and caspase-3 decreased with the prolongation of therapeutic time. Typical hepatocyte apoptosis was obviously ameliorated under electron microscope with the prolongation of therapeutic time. CONCLUSION: SNMC can effectively protect liver against FHF induced by LPS/D-Gal N. SNMC can prevent hepatocyte apoptosis by inhibiting inflammatory reaction and stabilizing mitochondria membrane to suppress the release of Cyt-C and sequent activation of caspase-3. 相似文献
15.
Noterdaeme T Longrée L Bataille C Deroover A Lamproye A Delwaide J Beguin Y Honoré P Detry O 《World journal of gastroenterology : WJG》2011,17(25):3069-3072
Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases.Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure.Liver transplantation (LT) currently remains the only definitive treatment option for such cases,but is generally denied to patients suffering from malignancy.Here,the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure ... 相似文献
16.
AIM: To determine the seroprevalence of hepatitis C virus (HCV) and its co-infection with hepatitis B virus (HBV), hepatitis delta agent (HDV) and human immunodeficiency virus (HIV) among liver disease patients of south Tamil Nadu.METHODS: A total of 1012 samples comprising 512 clinically diagnosed cases of liver disease patients and 500 apparently healthy age and sex matched individuals were screened for Hepatitis C virus (anti HCV and HCV RNA), Hepatitis B virus (HBsAg), Hepatitis delta agent (anti HDV) and Human immuno virus (antibodies to HIV-1 and HIV-2) using commercially available enzyme linked immunosorbent assay kits. HCV RNA was detected by RT-PCR. Liver function tests like ALT, AST, GGT, ALP, bilirubin and albumin were also studied.RESULTS: The seroprevalence of HCV was found to be 5.6% among liver disease patients by ELISA. 27/512, 49/512 and 12/512 patients were positive for HIV, HBV & HDV respectively. Co-infection of HCV & HBV was found in 8 patients, with 6 for HCV & HIV and 4 for HCV, HBV & HIV co-infections. Sex-wise analysis showed that HIV, HCV & HBV and HCV & HIV co-infection was high among females whereas for HBV it was high in males. The mean ALT and AST in HCV positive cases were 42.1 ± 8.3 and 49 ± 10.1. In people co-infected with HCV & HBV or HCV & HIV or HCV, HBV & HIV the mean ALT of 58.0 ± 03.16, 56.78 ± 4.401 and 64.37 ± 4.01 respectively.CONCLUSION: We strongly recommend routine test of the blood for HCV in addition to HBV and HIV. We also recommend individualized counseling to identify those at risk and testing for those who want it. Improved surveillance and periodic epidemiological studies will have to be undertaken to monitor and prevent these blood-borne viruses. 相似文献
17.
Yukiya Hakozaki Makoto Yoshiba Kazuhiko Sekiyama Eiji Seike Junichi Iwamoto Keiji Mitani Masafumi Mine Toshio Morizane Katsuki Ohtani Yasuhiko Suzuki Nobutaka Wakamiya 《Liver international》2002,22(1):29-34
Abstract: Background/Aims: The mannose‐binding lectin (MBL) gene was reported to play an important role in determining the clinical outcome of persistent hepatitis B virus (HBV) infection. We investigated serum MBL concentrations and MBL gene mutations to determine whether they were related to the prognosis of patients with fulminant hepatic failure (FHF) caused by HBV infection. Methods: We investigated serum MBL concentrations and MBL gene mutations in 43 HBV‐infected Japanese patients with FHF and 260 HBsAg‐negative healthy controls. Serum MBL concentrations were measured by an enzyme‐linked immunosorbent assay, and mutations in the MBL gene were analysed by nested PCR and direct DNA sequencing. Results: Only a mutation in codon 54 of the MBL gene was found. The frequency of this mutation in nonsurvivors (40%, 8/20) was higher than in survivors (13%, 3/23), and the difference was slightly significant (p = 0.043). The H allele frequency in survivors (70.5%, 31/44) was higher than in nonsurvivors (39.5%, 15/38) (p = 0.0048). Because of these factors the mean serum MBL concentration in survivors, 1.61 μg/ml (range 0.3–3.86), was significantly higher than in nonsurvivors, 0.79 μg/ml (range 0.04–1.51) (p < 0.0001). The likelihood ratio for nonsurvival was 0 for over 2.0 μg/ml, 0.67 for 1.0–2.0 μg/ml, and 2.24 for 0–1.0 μg/ml. Conclusions: The mutation in codon 54 of the MBL gene tended to be higher in nonsurvivors than in survivors. The H allele frequency (high producing allele in H/Y) in survivors was higher than that in nonsurvivors. High levels of serum MBL correlated with the survival of patients with FHF due to HBV infection. Serum MBL may be useful as a predictive factor for the survival of patients with FHF caused by HBV. 相似文献
18.
Bing-Zhu Yan Wei Wang Li-Yan Chen Man-Ru Bi Yan-Jie Lu Bao-Xin Li Bao-Shan Yang 《World journal of gastroenterology : WJG》2009,15(10):1231-1236
AIM: To investigate the pathogenic role of cathepsin B and the protective effect of a cathepsin B inhibitor (CA-074Me) in fulminant hepatic failure in mice.METHODS: LPS/D-Gal N was injected into mice of the model group to induce fulminant hepatic failure;the protected group was administered CA-074me for 30 min before LPS/D-Gal N treatment; the normal group was given isochoric physiologic saline. Liver tissue histopathology was determined with HE at 2,4, 6 and 8 h after Lps/D-Gal injection. Hepatocyte apoptosis was examined by TUNEL method. The expression of cathepsin B in liver tissues was investigated by immunohistochemistry, Western blot and RT-PCR.RESULTS: Compared with the normal group, massive typical hepatocyte apoptosis occurred in the model group; the number of apoptotic cells reached a maximum 6 h after injection. The apoptosis index (AI) in the protected group was clearly reduced (30.4$$$$markedly increased in drug-treated mice compared with the normal group ( P < 0.01). Incubation with LPS/D-Gal N at selected time points resulted in a timedependent increase in cathepsin B activity, and reached a maximum by 8 h. The expression of cathepsin B was significantly decreased in the protected group ( P <0.01).CONCLUSION: Cathepsin B plays an essential role in the pathogenesis of fulminant hepatic failure, and the cathepsin B inhibitor CA-074me can attenuate apoptosis and liver injury. 相似文献
19.
HCV HBV感染与肝细胞性肝癌 总被引:1,自引:0,他引:1
调查了肝癌高发地区不同肝病患者中丙型肝炎病毒(HCV)感染率。慢性肝病患者绝大多数已被乙型肝炎病毒(HBV)感染。HCV第二代抗体阳性率,肝癌7.3%,肝硬化6.6%,慢性肝炎6.6%和急性肝炎3.4%。两种病毒的复合感染率,肝癌5.1%,肝硬化1.7%,慢性肝炎3.9%和急性肝炎1.1%。在38例HCV抗体阳性的慢性肝病患者中,ALT异常84.2%,有输血史者占57.9%,HCV-RNA阳性率为71.1%。本研究的资料分析提示,在肝癌高发地区尽管HCV抗体阳性率较低,但HCV感染也是肝癌发生的重要病因之一。 相似文献
20.
Increased serum and hepatic tissue levels of interleukin-18 in patients with fulminant hepatic failure 总被引:6,自引:0,他引:6
Shinoda M Wakabayashi G Shimazu M Saito H Hoshino K Tanabe M Morikawa Y Endo S Ishii H Kitajima M 《Journal of gastroenterology and hepatology》2006,21(11):1731-1736
BACKGROUND: Fulminant hepatic failure is a serious clinical condition associated with a high mortality rate. Interleukin (IL)-18 is a pro-inflammatory cytokine that is associated with several inflammatory diseases. The purpose of the present paper was therefore to investigate whether IL-18 is elevated in patients with fulminant hepatic failure. METHODS: Serum levels of IL-18 were measured in patients with fulminant hepatic failure before and after liver transplantation. Native liver tissue samples were collected and the tissue levels of IL-18 were determined. Liver tissues were stained immunohistochemically with antihuman IL-18 antibody. The serum levels of IL-1beta, IL-6, IL-8, IL-12, interferon-gamma, and tumor necrosis factor-alpha were also determined in patients with fulminant hepatic failure before and after liver transplantation. RESULTS: Elevated levels of IL-18 in serum and hepatic tissue were observed in patients with fulminant hepatic failure. Native liver tissue samples were immunohistochemically positive for IL-18. Interleukin-18 levels were markedly reduced after liver replacement. No other inflammatory cytokines were substantially elevated in patients with fulminant hepatic failure. CONCLUSION: The serum levels of IL-18 levels are elevated much more than those of other cytokines in patients with fulminant hepatic failure. 相似文献